KR20220124177A - 급성 골수성 백혈병 또는 골수형성이상증후군의 치료방법 - Google Patents

급성 골수성 백혈병 또는 골수형성이상증후군의 치료방법 Download PDF

Info

Publication number
KR20220124177A
KR20220124177A KR1020227023046A KR20227023046A KR20220124177A KR 20220124177 A KR20220124177 A KR 20220124177A KR 1020227023046 A KR1020227023046 A KR 1020227023046A KR 20227023046 A KR20227023046 A KR 20227023046A KR 20220124177 A KR20220124177 A KR 20220124177A
Authority
KR
South Korea
Prior art keywords
compound
lymphoma
leukemia
cell
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227023046A
Other languages
English (en)
Korean (ko)
Inventor
마크 알. 브레이
재클린 엠. 메이슨
그레이엄 플레처
Original Assignee
유니버시티 헬스 네트워크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 헬스 네트워크 filed Critical 유니버시티 헬스 네트워크
Publication of KR20220124177A publication Critical patent/KR20220124177A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020227023046A 2019-12-06 2020-12-04 급성 골수성 백혈병 또는 골수형성이상증후군의 치료방법 Pending KR20220124177A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962944876P 2019-12-06 2019-12-06
US62/944,876 2019-12-06
PCT/CA2020/051668 WO2021108918A1 (en) 2019-12-06 2020-12-04 Treatment for acute myeloid leukemia or myelodysplastic syndrome

Publications (1)

Publication Number Publication Date
KR20220124177A true KR20220124177A (ko) 2022-09-13

Family

ID=76221282

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227023046A Pending KR20220124177A (ko) 2019-12-06 2020-12-04 급성 골수성 백혈병 또는 골수형성이상증후군의 치료방법

Country Status (12)

Country Link
US (1) US12533357B2 (https=)
EP (1) EP4069246A4 (https=)
JP (1) JP2023505301A (https=)
KR (1) KR20220124177A (https=)
CN (1) CN115397429A (https=)
AU (1) AU2020396807A1 (https=)
BR (1) BR112022011052A2 (https=)
CA (1) CA3163796A1 (https=)
IL (1) IL293623A (https=)
MX (1) MX2022006910A (https=)
TW (1) TWI880995B (https=)
WO (1) WO2021108918A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7337539B2 (ja) * 2018-06-21 2023-09-04 メディヴィル・アクチエボラーグ 白血病療法のための塩基修飾シチジンヌクレオチド
JP7717842B2 (ja) 2021-05-11 2025-08-04 オリック ファーマシューティカルズ，インク． ポロ様キナーゼ４阻害剤
US20250049787A1 (en) * 2021-12-22 2025-02-13 University Health Network Treatment for acute myeloid leukemia or lymphoma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2465971T3 (es) 2009-04-06 2014-06-09 University Health Network Inhibidores de quinasa y método para tratar cáncer con los mismos
SI2556071T1 (sl) * 2010-04-06 2016-12-30 University Health Network Kinazni inhibitorji in njihova uporaba pri zdravljenju raka
ES2706066T3 (es) * 2010-07-02 2019-03-27 Univ Health Network Procedimiento dirigido a enfermedades mutantes con PTEN y composiciones para las mismas
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
WO2015051304A1 (en) 2013-10-04 2015-04-09 Aptose Biosciences Inc. Compositions, biomarkers and their use in treatment of cancer
HUE043194T2 (hu) * 2013-10-18 2019-08-28 Univ Health Network PLK-4 inhibitor sója és kristályformái
US9566280B2 (en) 2014-01-28 2017-02-14 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
JP6617208B2 (ja) 2017-03-31 2019-12-11 ノバルティス アーゲー 血液腫瘍におけるｈｄｍ２−ｐ５３相互作用阻害剤の用量およびレジメン
WO2019046949A1 (en) * 2017-09-08 2019-03-14 University Health Network POLYTHERAPIES FOR INHIBITING KINASE 4 OF THE POLO TYPE
EP3720560A4 (en) * 2017-12-06 2022-01-05 Ludwig Institute for Cancer Research Ltd METHOD OF TREATMENT OF CANCER WITH PLK4 INHIBITORS

Also Published As

Publication number Publication date
CN115397429A (zh) 2022-11-25
US12533357B2 (en) 2026-01-27
WO2021108918A1 (en) 2021-06-10
AU2020396807A1 (en) 2022-07-21
CA3163796A1 (en) 2021-06-10
MX2022006910A (es) 2022-11-09
TWI880995B (zh) 2025-04-21
BR112022011052A2 (pt) 2022-08-16
EP4069246A4 (en) 2023-12-06
EP4069246A1 (en) 2022-10-12
TW202134237A (zh) 2021-09-16
JP2023505301A (ja) 2023-02-08
IL293623A (en) 2022-08-01
US20230010772A1 (en) 2023-01-12

Similar Documents

Publication Publication Date Title
US20120295864A1 (en) Method for treating acute myeloid leukemia
US12533357B2 (en) Treatment for acute myeloid leukemia or myelodysplastic syndrome
JP7266030B2 (ja) リンパ球悪性疾患を治療するための方法
AU2012321110A1 (en) Combination treatment
AU2013402794A1 (en) Cancer treatment with combination of plinabulin and taxane
WO2013184621A1 (en) Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
EP2928456B1 (en) Treatment of hematological cancer refractory to an anti-cancer agent
US20230132982A1 (en) Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma
TWI849001B (zh) Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物
CN113509475A (zh) Bcl-2/bcl-xl抑制剂的组合及相关用途
US20250049787A1 (en) Treatment for acute myeloid leukemia or lymphoma
EA049792B1 (ru) Лечение острого миелоидного лейкоза или миелодиспластического синдрома
US20160331755A1 (en) Pharmaceutical Combinations
KR20240108437A (ko) 면역성 혈소판 감소증 치료에 있어서 퀴놀리논 유도체의 용도
TW202308641A (zh) 用於治療癌症之方法及包含cdk抑制劑之給藥方案
US20240335440A1 (en) Combination therapy comprising a pkc inhibitor and a c-met inhibitor
WO2025208443A1 (en) Methods of treatment warm autoimmune hemolytic anemia using sovleplenib
CN121285550A (zh) 一种吡咯并[2,3-c]吡啶酮化合物的联用药物组合物及其用途
HK40078137A (en) Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma
Sears et al. 2008 new drug approvals
EP2994126A1 (en) Combination of a pi3 kinase inhibitor with paclitaxel for use in the treatment or prevention of a cancer of the head and neck

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902